Blood Cancer Journal (Feb 2023)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

Rimal Ilyas,
Kristen McCullough,
Talha Badar,
Mrinal M. Patnaik,
Hassan Alkhateeb,
Abhishek Mangaonkar,
Animesh Pardanani,
Ayalew Tefferi,
Naseema Gangat

Affiliations

Rimal Ilyas: Division of Hematology, Mayo Clinic
Kristen McCullough: Division of Hematology, Mayo Clinic
Talha Badar: Division of Hematology, Mayo Clinic
Mrinal M. Patnaik: Division of Hematology, Mayo Clinic
Hassan Alkhateeb: Division of Hematology, Mayo Clinic
Abhishek Mangaonkar: Division of Hematology, Mayo Clinic
Animesh Pardanani: Division of Hematology, Mayo Clinic
Ayalew Tefferi: Division of Hematology, Mayo Clinic
Naseema Gangat: Division of Hematology, Mayo Clinic

DOI: https://doi.org/10.1038/s41408-023-00800-2
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 3

Abstract

No abstracts available.

Published in Blood Cancer Journal

ISSN: 2044-5385 (Online)
Publisher: Nature Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.nature.com/bcj/index.html

About the journal